Afficher la couverture 'Cell-of-Origin (COO) Classification, BCL2 and MYC Expression Associated Outcome in Younger Patients Treated By RCHOP Front-Line Therapy Versus Intensive Regimen Followed By Autologous Transplant for De Novo Advanced Diffuse Large B Cell Lymphoma (DLBCL) : Results of the French Prospective Multicenter Randomized Trial Goelams-075 | Laboure, Gaëlle' en grand format
/5

0 avis

Cell-of-Origin (COO) Classification, BCL2 and MYC Expression Associated Outcome in Younger Patients Treated By RCHOP Front-Line Therapy Versus Intensive Regimen Followed By Autologous Transplant for De Novo Advanced Diffuse Large B Cell Lymphoma (DLBCL) : Results of the French Prospective Multicenter Randomized Trial Goelams-075

Archive ouverte

Laboure, Gaëlle | Parrens, Marie-Cecile | Tsaranazy, Anjarasoa | Bordier, Magali | Le Gouill, Steven | Delwail, Vincent | Gressin, Rémy | Cornillon, Jerome | Damaj, Gandhi | Foussard, Charles Yves | Maisonneuve, Hervé | Deconinck, Eric | Cartron, Guillaume | Dreyfus, François | Gyan, Emmanuel | Sutton, Laurent | Morineau, Nadine | Alexis, Magda | Banos, Anne | Damotte, Diane | Moreau, Anne | Kraeber-Bodéré, Françoise | Rossille, Delphine | Fest, Thierry | Lamy, Thierry | Milpied, Noel

Edité par CCSD -

WOS:000368021800177. International audience. The prognostic value of COO classification by immunohistochemistry (IHC) for de novo untreated advanced DLBCL remains controversial after Rituximab-based frontline therapy. Other biomarkers such as BCL2 or MYC protein expression have been proposed to predict survival. IHCcharacteristics were investigated in a large multicenter randomized study.

Suggestions

Du même auteur

The negative influence of baseline cell-free DNA on long-term survival in DLBCL depends on frontline treatment intensity

Archive ouverte | Desmots-Loyer, Fabienne | CCSD

International audience. Purpose - This study aims to investigate the relationship between the intensity of the initial treatment given to patients with de novo diffuse large B-cell lymphoma (DLBCL) and the impact of...

R-CHOP 14 with or without radiotherapy in non-bulky limited-stage diffuse large B-cell lymphoma (DLBCL)

Archive ouverte | Lamy, Thierry | CCSD

International audience. The benefit of radiotherapy (RT) after chemotherapy in limited-stage diffuse large B-cell lymphoma (DLBCL) remains controversial. We conducted a randomized trial in patients with nonbulky lim...

Prognostic value of high-sensitivity measurable residual disease assessment after front-line chemoimmunotherapy in chronic lymphocytic leukemia

Archive ouverte | Letestu, Rémi | CCSD

International audience. Measurable residual disease (MRD) status is widely adopted in clinical trials in patients with chronic lymphocytic leukemia (CLL). Findings from FILO group trials (CLL2007FMP, CLL2007SA, CLL2...

Chargement des enrichissements...